Search

Your search keyword '"Kahraman, Seda"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Kahraman, Seda" Remove constraint Author: "Kahraman, Seda" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
38 results on '"Kahraman, Seda"'

Search Results

1. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

2. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

4. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

5. Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

6. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

7. Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

10. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

11. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group

12. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

13. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

14. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

16. Geriatrik hastada dental uygulama esnasında implant anahtarının aspirasyonu: vaka raporu

17. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

19. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

20. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

21. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

22. Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations.

23. Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma

24. We need a common definition and treatment algorithm for displaced rib fracture

25. Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer

27. A Generalized Construction for Perfect Autocorrelation Sequences

29. Polikistik over sendromu'nda serum dipeptidil peptidaz-4 (DPP-4), adenozin deaminaz (ADA) aktiviteleri ve oksidatif stres belirteçlerinin değerlendirilmesi

31. Siyanobakteriler ve toksinleri

32. Optimal frekans atlamalı diziler

33. Süzme ballarda muhafaza sıcaklığının HMF değeri ve diastaz aktivitesi üzerine etkisi

34. Trans fatty acids

35. Optimal frekans atlamalı diziler

36. A Rare Case of Metachronous Tumor: Recurrent Primary Lung Cancer.

37. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group).

38. [Clinical features of the ALK-mutant non-small cell lung cancer patients who received first-line alectinib treatment].

Catalog

Books, media, physical & digital resources